eLife1d
Pyrotinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (PERSIST): A multicenter phase II trial
Kaplan–Meier curves showed that extended adjuvant pyrotinib administered after trastuzumab-based adjuvant therapy provides a promising survival benefit in patients with high-risk HER2-positive breast ...
pharmaphorum6y
Roche’s Perjeta combo approved in Europe for early breast cancer
The European Commission (EC) has approved Roche’s Perjeta (pertuzumab) in combination with Herceptin (trastuzumab) and chemotherapy for post-surgery (adjuvant) treatment of adult patients with ...
CURE15d
Kadcyla Continues to Show Benefits in Early HER2+ Breast Cancer
In HER2-positive early breast cancer, Kadcyla shows sustained improvement in both invasive disease-free survival and overall ...
Business Wire7d
European Medicines Agency (EMA) Validates Henlius and Organon Filing for Perjeta ® (pertuzumab) Biosimilar Candidate HLX11
Pertuzumab has been approved in various countries and regions in combination with trastuzumab and chemotherapy for the neoadjuvant treatment of patients with HER2-positive, locally advanced ...
PMLiVE3d
Organon/Henlius announce EMA validation for Perjeta biosimilar HLX11
Perjeta holds approvals for multiple HER2-positive breast cancer indications, including in combination with trastuzumab and chemotherapy for the neoadjuvant treatment of patients with HER2-positive, ...
Joplin Globe8d
European Medicines Agency (EMA) Validates Henlius and Organon Filing for Perjeta® (pertuzumab) Biosimilar Candidate HLX11
Pertuzumab has been approved in various countries and regions in combination with trastuzumab and chemotherapy for the neoadjuvant treatment of patients with HER2-positive, locally advanced ...